BP
ABBV icon

Ballentine Partners’s AbbVie ABBV Stock Holding History

Ballentine Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
42,284
+1,510
+4% +$325K 0.13% 62
2026
Q1 		$8.87M Sell
40,774
-227
-0.6% -$50.4K 0.12% 65
2025
Q4 		$9.37M Buy
41,001
+368
+0.9% +$83.8K 0.13% 57
2025
Q3 		$9.41M Sell
40,633
-336
-0.8% -$68.4K 0.13% 59
2025
Q2 		$7.6M Sell
40,969
-1,367
-3% -$254K 0.11% 65
2025
Q1 		$8.87M Buy
42,336
+4,723
+13% +$918K 0.15% 58
2024
Q4 		$6.68M Buy
37,613
+23
+0.1% +$4.23K 0.11% 63
2024
Q3 		$7.42M Buy
37,590
+5,603
+18% +$1.05M 0.13% 60
2024
Q2 		$5.49M Buy
31,987
+708
+2% +$117K 0.1% 65
2024
Q1 		$5.7M Buy
31,279
+5,950
+23% +$1.03M 0.11% 65
2023
Q4 		$3.93M Sell
25,329
-2,419
-9% -$353K 0.08% 87
2023
Q3 		$4.14M Buy
27,748
+7,685
+38% +$1.13M 0.1% 80
2023
Q2 		$2.7M Sell
20,063
-6,161
-23% -$903K 0.06% 96
2023
Q1 		$4.18M Buy
26,224
+6,661
+34% +$1.02M 0.11% 74
2022
Q4 		$3.16M Buy
19,563
+1,903
+11% +$292K 0.09% 81
2022
Q3 		$2.37M Buy
17,660
+2,770
+19% +$397K 0.08% 86
2022
Q2 		$2.28M Buy
14,890
+234
+2% +$35.8K 0.08% 91
2022
Q1 		$2.38M Sell
14,656
-60
-0.4% -$8.72K 0.07% 97
2021
Q4 		$1.99M Buy
14,716
+1,581
+12% +$187K 0.06% 109
2021
Q3 		$1.42M Buy
13,135
+26
+0.2% +$2.97K 0.05% 132
2021
Q2 		$1.48M Buy
13,109
+780
+6% +$87.8K 0.05% 121
2021
Q1 		$1.33M Buy
12,329
+786
+7% +$84.1K 0.05% 127
2020
Q4 		$1.24M Sell
11,543
-2,665
-19% -$256K 0.05% 131
2020
Q3 		$1.24M Buy
14,208
+598
+4% +$56.3K 0.06% 116
2020
Q2 		$1.34M Buy
13,610
+1,109
+9% +$97.6K 0.06% 109
2020
Q1 		$951K Buy
12,501
+237
+2% +$20.2K 0.06% 126
2019
Q4 		$1.09M Buy
12,264
+86
+0.7% +$7.14K 0.05% 147
2019
Q3 		$922K Buy
12,178
+10
+0.1% +$686 0.04% 155
2019
Q2 		$886K Buy
12,168
+4,169
+52% +$328K 0.04% 158
2019
Q1 		$645K Sell
7,999
-1,150
-13% -$94.1K 0.03% 169
2018
Q4 		$844K Buy
9,149
+624
+7% +$54.9K 0.05% 138
2018
Q3 		$806K Buy
8,525
+770
+10% +$73K 0.04% 148
2018
Q2 		$719K Buy
7,755
+859
+12% +$83.9K 0.04% 149
2018
Q1 		$653K Hold
6,896
– – 0.04% 158
2017
Q4 		$667K Sell
6,896
-1,218
-15% -$115K 0.04% 157
2017
Q3 		$720K Sell
8,114
-3,295
-29% -$251K 0.04% 155
2017
Q2 		$822K Buy
11,409
+4,844
+74% +$326K 0.06% 146
2017
Q1 		$428K Sell
6,565
-1,798
-21% -$113K 0.03% 136
2016
Q4 		$523K Buy
8,363
+1,085
+15% +$66.2K 0.04% 105
2016
Q3 		$459K Sell
7,278
-575
-7% -$37.2K 0.04% 107
2016
Q2 		$486K Buy
7,853
+663
+9% +$40.4K 0.04% 111
2016
Q1 		$410K Buy
7,190
+255
+4% +$14.2K 0.04% 127
2015
Q4 		$411K Buy
6,935
+331
+5% +$19.1K 0.04% 110
2015
Q3 		$359K Sell
6,604
-35
-0.5% -$2.28K 0.04% 113
2015
Q2 		$446K Buy
6,639
+40
+0.6% +$2.61K 0.04% 100
2015
Q1 		$387K Sell
6,599
-97
-1% -$5.86K 0.04% 109
2014
Q4 		$438K Hold
6,696
– – 0.05% 98
2014
Q3 		$387K Buy
6,696
+12
+0.2% +$666 0.05% 101
2014
Q2 		$377K Sell
6,684
-287
-4% -$15.1K 0.04% 97
2014
Q1 		$358K Buy
6,971
+155
+2% +$7.83K 0.04% 101
2013
Q4 		$360K Hold
6,816
– – 0.04% 104
2013
Q3 		$305K Buy
6,816
+1,910
+39% +$84.7K 0.04% 108
2013
Q2 		$203K Buy
+4,906
New +$215K 0.03% 119

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ballentine Partners's ABBV Position: Q2 2026 in Review

Ballentine Partners increased its AbbVie (ABBV) stake by 3.7% in Q2 2026, buying an estimated $325K and bringing the position to 42,284 shares worth $10.6M. The position accounts for 0.13% of the portfolio, ranked #62.

Ballentine Partners first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ballentine Partners held 42,284 shares of AbbVie worth $10.6M as of Q2 2026.
  • Ballentine Partners bought 1,510 AbbVie shares in Q2 2026, an estimated $325K.
  • AbbVie made up 0.13% of Ballentine Partners's portfolio in Q2 2026, its #62 holding.
  • Ballentine Partners first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.